Access to innovative kidney treatments, ESRD PPS, coverage of oral only medications for people with ESRD, innovation, Drug pricing, Medicare access to pharmaceuticals
Source-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 19, 2026
- Income
- Not reported
- Expenses
- $580,000.00
- Registrant
- ARDELYX, INC.
- Client
- ARDELYX, INC.
- Filing UUID
- 1542d780-3a2b-4ef0-86c7-1846b2b3296c
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.